Search

Your search keyword '"Fagiuoli S."' showing total 479 results

Search Constraints

Start Over You searched for: Author "Fagiuoli S." Remove constraint Author: "Fagiuoli S." Database OAIster Remove constraint Database: OAIster
479 results on '"Fagiuoli S."'

Search Results

1. Extended criteria liver donation after circulatory death with prolonged warm ischemia: a pilot experience of normothermic regional perfusion and no subsequent ex-situ machine perfusion

2. A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: The 1969–1989 birth-cohort

3. Vaccination Recommendations in Solid Organ Transplant Adult Candidates and Recipients

4. Systemic treatment for hepatocellular carcinoma beyond milan criteria on the waitlist: is it time for a neoadjuvant therapy?

5. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study

6. The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients

7. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

8. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer

9. One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity

10. AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool

11. Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)

12. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

13. Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome

14. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis

15. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome

16. Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome

17. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

18. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

19. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness

20. Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study

21. Meet–Test–Treat for HCV management: patients’ and clinicians’ preferences in hospital and drug addiction services in Italy

22. Liver transplantation in patients with non-neoplastic portal vein thrombosis: 20 years of experience in a single center

23. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study

24. Current Endovascular Management of Arterial Complications After Pediatric Liver Transplantation in a Tertiary Center

25. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals

26. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis

27. Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients

28. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

29. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

30. Drug–drug interactions in italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: Insights from a real-world study

31. Pre-transplant alpha-fetoprotein > 25.5 and its dynamic on waitlist are predictors of HCC recurrence after liver transplantation for patients meeting milan criteria

32. Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19

33. Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction

34. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria

35. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients

36. Bergamo and Covid-19: How the Dark Can Turn to Light

37. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

38. Successful treatment of suspected donor-derived human herpesvirus-8 infection in a liver transplant patient with coronavirus disease-19

39. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

40. Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study

41. AFP at transplant is associated with a higher risk of HCC recurrence after liver transplantation for patients meeting Milano criteria

42. Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial

43. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

44. COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study

45. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

46. Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use

47. Correction to: Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group (Hepatology International, (2020), 14, 6, (930-943), 10.1007/s12072-020-10091-5)

48. Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x)

49. Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology

50. Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab

Catalog

Books, media, physical & digital resources